Silexion Therapeutics(SLXN.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Silexion Therapeutics
SLXN.US
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment.
1.883 T
SLXN.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Silexion Therapeutics CEO highlights successful pre-clinical study of SIL204: promising tumor inhibition in pancreatic, colorectal, and lung cancer models.

    SIL204 has shown noteworthy tumor inhibition in promising preclinical trials, displaying effectiveness against pancreatic, colorectal, and lung cancer models.

    Unusual Whales·
    US
    SLXN
    -1.32%
    Unusual Whales·
    US
    SLXN
    -1.32%

    Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements

    Silexion Therapeutics Corp. has published a shareholder letter from CEO Ilan Hadar, highlighting major achievements in 2025, including positive preclinical data for SIL204 and completion of regulatory toxicology studies. The letter also mentions positive feedback from Germany’s Federal Institute for Drugs and Medical Devices on the Phase 2⁄3 trial design and outlines plans to initiate a Phase 2⁄3 clinical trial in locally advanced pancreatic cancer in early 2026, along with expected milestones for the upcoming year.

    Reuters·
    US
    SLXN
    -1.32%
    Reuters·
    US
    SLXN
    -1.32%

    Silexion Therapeutics Reports Strong Preclinical Tumor Inhibition With SIL204 in KRAS-Mutated Cancers

    Silexion Therapeutics Corp. reported strong preclinical results for its RNAi therapy, SIL204, which showed significant tumor inhibition in KRAS-mutated cancers, including pancreatic, colorectal, and lung cancers. The findings, achieved in 2025, are set to be followed by human clinical trials in the first half of 2026. The company also received positive feedback from Germany’s BfArM on its Phase 2/3 trial design for SIL204 in locally advanced pancreatic cancer.

    Reuters·
    US
    SLXN
    -1.32%
    Reuters·
    US
    SLXN
    -1.32%

    Maxim Group Sticks to Its Buy Rating for Silexion Therapeutics (SLXN)

    Maxim Group's analyst Naz Rahman reiterated a Buy rating for Silexion Therapeutics (SLXN) with a price target of $12.00, despite the current share price of $2.61. Rahman, who has an average return of -10.6% and a 33.72% success rate, focuses on the Healthcare sector. The analyst consensus for Silexion Therapeutics is a Moderate Buy with an average price target of $9.00.

    Tip Ranks·
    US
    SLXN
    -1.32%
    Tip Ranks·
    US
    SLXN
    -1.32%

    Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | SLXN Stock News

    Silexion Therapeutics has submitted a Phase 2/3 clinical trial application in Israel for SIL204, targeting locally advanced pancreatic cancer. This marks a key milestone following successful toxicology studies and positive feedback from German regulators. The trial is set to begin in Q2 2026, with further regulatory filings planned in Germany and the EU. The application is in collaboration with Sheba Medical Center, and U.S. expansion is anticipated post-safety run-in. SIL204 aims to silence mutated KRAS oncogenes, addressing unmet needs in pancreatic cancer treatment.

    StockTitan·
    US
    SLXN
    -1.32%
    StockTitan·
    US
    SLXN
    -1.32%
    © 2026 Longbridge｜Disclaimer